Pfizer’s BRAFTOVI Regimen Nearly Doubles Progression-Free Survival in mCRC
The Phase 3 BREAKWATER study showed BRAFTOVI combined with cetuximab and FOLFIRI nearly doubled median progression-free survival to 15.2 months compared to 8.3 months with the comparator.